PRINCETON, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announced that it will make two presentations highlighting clinical data on the safety and efficacy of VB-1953 for the treatment of moderate to severe inflammatory acne at the 77th Society for Investigative Dermatology (SID) Annual Meeting, being held in Chicago from May 8-11, 2019. VB-1953 is the first bactericidal antibiotic topical gel formulation for the treatment of acne vulgaris capable of not only reducing infection due to P. acnes with anti-inflammation action, but also retarding antibacterial resistance.
Details for the presentations are as follows:
| Presentation Title: | A proof of concept clinical study to test the efficacy and safety of VB1953 in moderate to severe acne subjects | ||
| Session: | Poster Session III | ||
| Date/Time: | May 11, 2019 from 12:45pm – 2:45pm CDT | ||
| Abstract Number: | 622 | ||
| Location: | Stevens Salons B-D, Hilton Chicago | ||
| Presentation Title: | A clinical study to test the efficacy of VB1953 in clindamycin non-responder acne patients with Clindamycin resistant P. acnes | ||
| Session: | Poster Session III | ||
| Date/Time: | May 11, 2019 from 12:45pm – 2:45pm CDT | ||
| Abstract Number: | 608 | ||
| Location: | Stevens Salons B-D, Hilton Chicago | ||
About VB-1953
Vyome’s lead molecule, VB-1953, is a first-in-class topical bactericidal antibiotic clinical drug candidate with a novel mechanism of action that includes inflammation-reducing capabilities as well as the demonstrated ability to treat antibiotic resistant P. acnes strains. VB-1953 is currently being studied in a Phase 2 clinical trial in the United States. In preclinical studies, VB-1953 showed activity against clindamycin-resistant P. acnes bacteria, a low emergence of resistance and the ability to reduce inflammation via an immunomodulatory effect. VB-1953 is delivered with a microtechnology gel system that ensures the drug is retained at the site of infection and minimizes systemic exposure. Acne caused by antibiotic-resistant P.acnes currently poses an emerging and unmet need for patients worldwide, with a potential $2B market opportunity in the US alone.
About Vyome Therapeutics
Vyome Therapeutics is a clinical stage specialty pharmaceutical company based in Princeton, New Jersey, developing a deep pipeline of drugs for the treatment of drug-resistant skin pathogens, including antibiotic-resistant P. acnes. Vyome recently closed a $22 million fund raise in January 2019 from new and existing investors, including Perceptive Advisors, Romulus and Iron Pillar. Vyome advanced its lead clinical candidate, VB-1953, into a Phase 2 clinical trial for the treatment of moderate to severe acne.
Vyome has a deep pipeline of preclinical new chemical entities, based on its patented Dual Action Rational Therapeutics (DARTs) technology, which are unique in their ability to overcome antimicrobial resistance. Vyome has developed clinically validated antifungal products based on its innovative and patented technology platform Molecular Replacement Therapeutics (MRT™), a platform for which Vyome has recently signed an out-licensing deal of marketing rights with a large specialty pharmaceutical company. More information is available at http://www.vyometx.com and @VyomeTx.
Media contact:
Michael Tattory
LifeSci Public Relations
(646) 751-4362
mtattory@lifescipublicrelations.com